Our study provides a mechanistic link among human genetic variation, JMJD3 expression in SMCs associated with BP alterations, and an SMC phenotypic switch in a murine model and also identifies a genetic target that may be used to develop previously unknown anti-HTN therapies. The gene discussed is KDM6B; the disease is hypertensive disorder.